Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block

Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.

Postoperative Pain

Breast Cancer

Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels

10 cc of 0.375% ropivacaine pectoral nerve block

University of New Mexico Hospital

Pectoral Nerve Blockade in Mastectomy

Improvement of Analgesia With Addition of Pectoral Nerve Block to Thoracic Paravertebral Blocks in Unilateral Total Simple Mastectomy

Timothy R Petersen

Research Information Specialist

Patients receiving IV scopolamine at ECT treatment

Patients receiving IV placebo at ECT treatment

Patients receiving IV scopolamine at ECT treatment
Scopolamine: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT

Scopolamine

Patients receiving IV placebo at ECT treatment
Scopolamine: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT

Placebo

Total

Sex: Female, Male

Region of Enrollment

Change in Ham D 17 scores measured by the difference between baseline HAM D score and HAM D score at last ECT administration. The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression. A negative change score refers to a decrease in HAM D score, while a positive change score would refer to an increase in HAM D score.

Change in Ham D 17 Scores

The number of days between baseline HAM D score and HAM D score showing response (defined as a HAM D score less than half of baseline). If patients HAM D score rose above this marker at any point in the study, they were not considered as responding.The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression. .

Time to Response for Patients Receiving ECT

The number of ECT treatments needed to achieve response (defined as a HAM D score less than half of baseline) and remission (defined as a HAM D score of less than 8). If patients HAM D score rose above these markers at any point in the study, they were not considered as responding or remitting.The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression.

Number of ECT Treatments Received to Achieve Response/Remission

The number of ECT treatments withheld during the course of the study due to cognitive impairment. In these cases, the participant would still be enrolled in the study but have a reduced # of ECTs. This outcome measure does not include patients who withdrew from the study.

Number of ECT Treatments Withheld Due to Cognitive Impairment

The mean number of adverse events classified as moderate to severe.

The Mean Number of Moderate to Severe Side Effects

Blood pressure was taken immediately post ECT administration at each ECT visit. We averaged Blood pressure for each participant at each ECT administration. The reported mean refers to the average among all participants in each group.

The Mean Levels of Physiological Measures of ECT (Blood Pressure)

Heart rate was taken immediately post ECT administration at each ECT visit. We averaged heart rate for each participant at each ECT administration. The reported mean refers to the average among all participants in each group.

The Mean Levels of Physiological Measures of ECT (Heart Rate)

Mean duration in seconds of the seizure induced by ECT for each participant at each ECT administration they received.The reported mean refers to the average among all participants in each group.

The Mean Levels of Physiological Measures of ECT (Seizure Duration)

Mean energy needed to induce the seizure for each participant at each ECT administration they received. The reported mean refers to the average among all participants in each group.

The Mean Levels of Physiological Measures of ECT (Energy Needed)

Overall Study

Dr. John Matthews

Depression

Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT

Massachusetts General Hospital

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

A Pilot Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

John D. Matthews

Principal Investigator, Assistant Professor of Psychiatry, Harvard Medical School

IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h

scopolamine/seizures

Pectoral Nerve Blockade in Mastectomy

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

Scopolamine Treatment for Patients With Organophosphate Poisoning

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi